What type of study is this?

This is a Pre-Registered Trial study.

September 10, 2025

Live Virus SARS-CoV-2 - iPSCPneumocyte - Antiviral Screening v1

Key Points

The antiviral candidates show varied efficacy against live virus SARS-CoV-2, with drug activity assessed via IC50 values.
Immunofluorescent staining provides data on the antiviral effects, enabling comparison between candidates in iPSC pneumocyte cells.
Cytotoxicity screening complements the live virus assays to determine the safety and toxicity of the antiviral candidates.
The results could guide future antiviral drug development strategies targeting SARS-CoV-2.

Abstract

The following is a protocol for live virus antiviral screening against SARS-CoV-2 in iPSC pneumocyte cells. iPSC pneumocytes are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against SARS-CoV-2. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay to investigate drug toxicity.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Briana L McGovern (Thu,) studied this question.

synapsesocial.com/papers/68c1e07554b1d3bfb60fce09 https://doi.org/https://doi.org/10.17504/protocols.io.36wgqne6kgk5/v1

Ask AI

Helpful

Bookmark

View Full Paper